{"id":"W4401435914","doi":"10.1093/bjd/ljae266.039","title":"661 - Efficacy and safety of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis (AD): a phase 2b trial (STREAM-AD)","year":2024,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"","keywords":"Medicine; Placebo; Clinical endpoint; Atopic dermatitis; Internal medicine; Clinical trial; Randomized controlled trial; Eczema Area and Severity Index; Double blind; Gastroenterology; Immunology; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00119919,0.0009443617,0.001449678,0.0002649111,0.0002735816,0.0006910941,0.0003919261,0.0008787782,0.005279182],"category_scores_gemma":[0.0006466866,0.0003152899,0.0009916915,0.0001976599,0.0004766247,0.0005889615,0.00022055,0.001510849,0.001005941],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004929227,"about_ca_system_score_gemma":0.0007766588,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003873267,"about_ca_topic_score_gemma":0.001093302,"domain_scores_codex":[0.9997068,0.0001492683,0.00002090459,0.00004648979,0.00002980805,0.0000468181],"domain_scores_gemma":[0.9996887,0.00006459487,0.00006729646,0.00001782334,0.00003320914,0.0001283333],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8919231,0.01952887,0.00384677,0.001225603,0.0008304012,0.0000989546,0.00007719067,0.0004315294,0.01859759,0.0001795761,0.003244039,0.06001634],"study_design_scores_gemma":[0.8238606,0.1637703,0.00791127,0.00005734954,0.0004318601,0.0001084369,0.00002244243,0.0005009202,0.001200551,0.0001145087,0.002008411,0.00001343728],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9905771,0.003988439,0.0001987492,0.0003957877,0.0002007653,0.001741637,0.0007176454,0.00006413994,0.002115821],"genre_scores_gemma":[0.9893037,0.002246768,0.001041379,0.0009634182,0.000378554,0.001816531,0.001365824,0.00001304194,0.002870801],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005279182,"threshold_uncertainty_score":0.01766062,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008430683096162642,"score_gpt":0.2847186414980553,"score_spread":0.2762879584018926,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}